The Journal of Clinical Investigation (Jan 2023)

Longitudinal liver sampling in patients with chronic hepatitis B starting antiviral therapy reveals hepatotoxic CD8+ T cells

  • Shirin Nkongolo,
  • Deeqa Mahamed,
  • Adrian Kuipery,
  • Juan D. Sanchez Vasquez,
  • Samuel C. Kim,
  • Aman Mehrotra,
  • Anjali Patel,
  • Christine Hu,
  • Ian McGilvray,
  • Jordan J. Feld,
  • Scott Fung,
  • Diana Chen,
  • Jeffrey J. Wallin,
  • Anuj Gaggar,
  • Harry L.A. Janssen,
  • Adam J. Gehring

Journal volume & issue
Vol. 133, no. 1

Abstract

Read online

Accumulation of activated immune cells results in nonspecific hepatocyte killing in chronic hepatitis B (CHB), leading to fibrosis and cirrhosis. This study aims to understand the underlying mechanisms in humans and to define whether these are driven by widespread activation or a subpopulation of immune cells. We enrolled CHB patients with active liver damage to receive antiviral therapy and performed longitudinal liver sampling using fine-needle aspiration to investigate mechanisms of CHB pathogenesis in the human liver. Single-cell sequencing of total liver cells revealed a distinct liver-resident, polyclonal CD8+ T cell population that was enriched at baseline and displayed a highly activated immune signature during liver damage. Cytokine combinations, identified by in silico prediction of ligand-receptor interaction, induced the activated phenotype in healthy liver CD8+ T cells, resulting in nonspecific Fas ligand–mediated killing of target cells. These results define a CD8+ T cell population in the human liver that can drive pathogenesis and a key pathway involved in their function in CHB patients.

Keywords